Oncogene - Table of Contents alert Volume 35 Issue 5

If you are unable to see the message below, click here to view.

Advertisement New! Pure and high quality exosome isolation - the perfect solution Ultra pure Ready to use with antibody-conjugated beads and optimized BSA-free buffers Sample diversity: serum, plasma, and cell culture supernatant Ideal for analysis of RNA, protein, Western blot, ELISA, flow cytometry, and more! Learn more. TABLE OF CONTENTS Volume 35, Issue 5 (February 2016) In this issue Review Original Articles Short Communication Retraction Also new AOP Advertisement Oncogenesis is an online-only, open access journal exploring the molecular basis of cancer and related phenomena. The journal seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics. The journal has an Impact Factor of 3.952. Explore the benefits of submitting your next research article. Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Oncogenesis is an online-only, open access journal exploring the molecular basis of cancer and related phenomena. The journal seeks to promote diverse and integrated areas of molecular biology, cell biology, oncology, and genetics. The journal has an Impact Factor of 3.952. Explore the benefits of submitting your next research article.  Review Top Role of Merlin/NF2 inactivation in tumor biology A M Petrilli and C Fernández-Valle Oncogene 2016 35: 537-548; advance online publication, April 20, 2015; 10.1038/onc.2015.125 Abstract | Full Text Original Articles Top Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression A Shvab, G Haase, A Ben-Shmuel, N Gavert, T Brabletz, S Dedhar and A Ben-Ze'ev Oncogene 2016 35: 549-557; advance online publication, April 27, 2015; 10.1038/onc.2015.127 Abstract | Full Text Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors OPEN V Gibaja, F Shen, J Harari, J Korn, D Ruddy, V Saenz-Vash, H Zhai, T Rejtar, C G Paris, Z Yu, M Lira, D King, W Qi, N Keen, A Q Hassan and H M Chan Oncogene 2016 35: 558-566; advance online publication, April 20, 2015; 10.1038/onc.2015.114 Abstract | Full Text NONO regulates the intra-S-phase checkpoint in response to UV radiation L Alfano, C Costa, A Caporaso, A Altieri, P Indovina, M Macaluso, A Giordano and F Pentimalli Oncogene 2016 35: 567-576; advance online publication, April 20, 2015; 10.1038/onc.2015.107 Abstract | Full Text Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors S M Haeger, J J Thompson, S Kalra, T G Cleaver, D Merrick, X-J Wang and S P Malkoski Oncogene 2016 35: 577-586; advance online publication, April 20, 2015; 10.1038/onc.2015.112 Abstract | Full Text Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma Á Ordóñez-Navadijo, E Fuertes-Yebra, B Acosta-Iborra, E Balsa, A Elorza, J Aragonés and M O Landazuri Oncogene 2016 35: 587-594; advance online publication, April 27, 2015; 10.1038/onc.2015.113 Abstract | Full Text SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1 C H Lin, S Y Liu and E H Y Lee Oncogene 2016 35: 595-607; advance online publication, April 13, 2015; 10.1038/onc.2015.115 Abstract | Full Text Identification of therapeutic targets for glioblastoma by network analysis D Friedmann-Morvinski, V Bhargava, S Gupta, I M Verma and S Subramaniam Oncogene 2016 35: 608-620; advance online publication, May 11, 2015; 10.1038/onc.2015.119 Abstract | Full Text Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability D-W Wu, C-Y Chen, C-L Chu and H Lee Oncogene 2016 35: 621-630; advance online publication, April 27, 2015; 10.1038/onc.2015.120 Abstract | Full Text Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway C-L Song, H Tang, L-K Ran, B C B Ko, Z-Z Zhang, X Chen, J-H Ren, N-N Tao, W-Y Li, A-L Huang and J Chen Oncogene 2016 35: 631-641; advance online publication, April 27, 2015; 10.1038/onc.2015.121 Abstract | Full Text Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells S Li, Y-T Oh, P Yue, F R Khuri and S-Y Sun Oncogene 2016 35: 642-650; advance online publication, April 20, 2015; 10.1038/onc.2015.123 Abstract | Full Text Brg-1 targeting of novel miR550a-5p/RNF43/Wnt signaling axis regulates colorectal cancer metastasis G Wang, Y Fu, X Yang, X Luo, J Wang, J Gong and J Hu Oncogene 2016 35: 651-661; advance online publication, May 11, 2015; 10.1038/onc.2015.124 Abstract | Full Text Short Communication Top HUS1 regulates in vivo responses to genotoxic chemotherapies G Balmus, P X Lim, A Oswald, K R Hume, A Cassano, J Pierre, A Hill, W Huang, A August, T Stokol, T Southard and R S Weiss Oncogene 2016 35: 662-669; advance online publication, April 27, 2015; 10.1038/onc.2015.118 Abstract | Full Text Retraction Top miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers G Vetter, A Saumet, M Moes, L Vallar, A Le Béchec, C Laurini, M Sabbah, K Arar, C Theillet, C-H Lecellier and E Friederich Oncogene 2016 35: 670; advance online publication, December 14, 2015; 10.1038/onc.2015.265 Full Text Advertisement BioPharma Dealmakers A supplement to Nature Biotechnology & Nature Reviews Drug Discovery Sign up to our NEW interactive website to connect with life sciences companies and partnering professionals looking for dealmaking opportunities. Stay up to date on emerging therapeutic areas with special editorial features. Ask for advice from our editors and experts in the field with private messaging, video chats, and community discussions. SIGN UP NOW   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.